Valuation Update With 7 Day Price Move • May 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €89.90, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €61.16 per share. Reported Earnings • May 13
First quarter 2026 earnings released: EPS: €0.36 (vs €0.25 in 1Q 2025) First quarter 2026 results: EPS: €0.36 (up from €0.25 in 1Q 2025). Revenue: €33.4m (up 25% from 1Q 2025). Net income: €3.46m (up 42% from 1Q 2025). Profit margin: 10% (up from 9.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year. Price Target Changed • May 12
Price target increased by 11% to €91.33 Up from €82.33, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of €88.00. Stock is up 68% over the past year. The company is forecast to post earnings per share of €2.58 for next year compared to €2.09 last year. Declared Dividend • May 02
Dividend increased to €1.20 Dividend of €1.20 is 20% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 1.5%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 18% per year over the past 8 years and payments have been stable during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Apr 30
Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026 Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026. Aankondiging • Mar 19
Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026 Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time. Reported Earnings • Mar 19
Full year 2025 earnings: Revenues exceed analyst expectations Full year 2025 results: Revenue: €134.0m (up 15% from FY 2024). Net income: €20.0m (up 20% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue exceeded analyst estimates by 1.1%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Buy Or Sell Opportunity • Mar 18
Now 30% overvalued after recent price rise Over the last 90 days, the stock has risen 40% to €74.80. The fair value is estimated to be €57.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Buy Or Sell Opportunity • Mar 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to €66.90. The fair value is estimated to be €55.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Buy Or Sell Opportunity • Feb 16
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to €64.70. The fair value is estimated to be €52.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 5.9%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €58.00, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Personal Products industry in Europe. Total loss to shareholders of 1.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.72 per share. Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €51.60, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Personal Products industry in Europe. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.66 per share. Buy Or Sell Opportunity • Nov 11
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 8.1% to €51.00. The fair value is estimated to be €41.95, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 3.4%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 58% in the next 2 years. New Risk • Oct 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 2.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (122% cash payout ratio). Share price has been volatile over the past 3 months (2.9% average weekly change). Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €46.85, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 17x in the Personal Products industry in Europe. Total loss to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.74 per share. Buy Or Sell Opportunity • Oct 02
Now 24% overvalued The stock has been flat over the last 90 days, currently trading at €46.85. The fair value is estimated to be €37.74, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 3.4%. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 49% in the next 2 years. Reported Earnings • Sep 11
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: €36.3m (up 11% from 2Q 2024). Net income: €6.75m (up 7.7% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe. Buy Or Sell Opportunity • Jun 02
Now 21% overvalued Over the last 90 days, the stock has fallen 8.5% to €50.80. The fair value is estimated to be €42.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Buy Or Sell Opportunity • May 16
Now 22% overvalued The stock has been flat over the last 90 days, currently trading at €51.90. The fair value is estimated to be €42.44, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Upcoming Dividend • Apr 28
Upcoming dividend of €1.00 per share Eligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Italian dividend payers (5.7%). Lower than average of industry peers (2.3%). Recent Insider Transactions • Apr 17
Delegate Advisor recently bought €132k worth of stock On the 11th of April, Carlo Volpi bought around 3k shares on-market at roughly €47.75 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Carlo has been a buyer over the last 12 months, purchasing a net total of €225k worth in shares. Reported Earnings • Mar 30
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: €1.73 (up from €1.33 in FY 2023). Revenue: €116.1m (up 15% from FY 2023). Net income: €16.6m (up 29% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Declared Dividend • Mar 19
Dividend increased to €1.00 Dividend of €1.00 is 18% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 2.0%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (58% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 17% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 49% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Mar 18
Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025 Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025. Aankondiging • Mar 06
Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025 Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time. New Risk • Jan 13
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 15
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Reported Earnings • Sep 11
Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023) Second quarter 2024 results: EPS: €0.67 (up from €0.19 in 2Q 2023). Revenue: €33.2m (up 27% from 2Q 2023). Net income: €6.27m (up 248% from 2Q 2023). Profit margin: 19% (up from 6.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year. Reported Earnings • May 17
First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023) First quarter 2024 results: EPS: €0.27 (down from €0.56 in 1Q 2023). Revenue: €24.0m (up 1.3% from 1Q 2023). Net income: €2.63m (down 52% from 1Q 2023). Profit margin: 11% (down from 23% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Upcoming Dividend • Apr 29
Upcoming dividend of €0.85 per share Eligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Italian dividend payers (5.7%). Lower than average of industry peers (2.1%). Reported Earnings • Mar 18
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: €1.33 (down from €1.56 in FY 2022). Revenue: €102.0m (up 23% from FY 2022). Net income: €12.8m (down 15% from FY 2022). Profit margin: 13% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Jan 14
Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024 Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023. Aankondiging • Jan 13
Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024 Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024 Reported Earnings • Nov 09
Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022) Third quarter 2023 results: EPS: €0.26 (down from €0.48 in 3Q 2022). Revenue: €22.3m (up 8.2% from 3Q 2022). Net income: €2.50m (down 46% from 3Q 2022). Profit margin: 11% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Sep 13
Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022) Second quarter 2023 results: EPS: €0.19 (down from €0.49 in 2Q 2022). Revenue: €25.9m (up 24% from 2Q 2022). Net income: €1.80m (down 62% from 2Q 2022). Profit margin: 7.0% (down from 23% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 18
First quarter 2023 earnings released First quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Personal Products industry in Italy. Upcoming Dividend • May 01
Upcoming dividend of €0.80 per share at 1.6% yield Eligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of Italian dividend payers (5.1%). Lower than average of industry peers (1.8%). Reported Earnings • Mar 18
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 20
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: €0.48 (up from €0.39 in 3Q 2021). Revenue: €20.5m (up 20% from 3Q 2021). Net income: €4.61m (up 20% from 3Q 2021). Profit margin: 23% (in line with 3Q 2021). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: €0.48 (up from €0.39 in 3Q 2021). Revenue: €20.8m (up 22% from 3Q 2021). Net income: €4.61m (up 20% from 3Q 2021). Profit margin: 22% (in line with 3Q 2021). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Sep 16
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Second quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 4.9%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 14
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: €0.36 (up from €0.26 in 1Q 2021). Revenue: €19.0m (up 33% from 1Q 2021). Net income: €3.49m (up 39% from 1Q 2021). Profit margin: 18% (in line with 1Q 2021). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Over the next year, revenue is forecast to grow 15%, compared to a 17% growth forecast for the industry in Italy. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 10
Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €17.0m (up 46% from 3Q 2020). Net income: €3.85m (up 122% from 3Q 2020). Profit margin: 23% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improved over the past week After last week's 18% share price gain to €62.40, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 32x in the Personal Products industry in Europe. Total returns to shareholders of 339% over the past three years. Price Target Changed • Aug 05
Price target increased to €59.33 Up from €53.67, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of €60.00. Stock is up 159% over the past year. Price Target Changed • Jun 16
Price target increased to €50.67 Up from €45.33, the current price target is an average from 3 analysts. New target price is 11% above last closing price of €45.60. Stock is up 93% over the past year. Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment improved over the past week After last week's 16% share price gain to €42.30, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 29x in the Personal Products industry in Europe. Total returns to shareholders of 225% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.58 per share. Price Target Changed • Jun 03
Price target increased to €45.00 Up from €42.00, the current price target is an average from 2 analysts. New target price is 25% above last closing price of €36.10. Stock is up 49% over the past year. Upcoming Dividend • Apr 26
Upcoming dividend of €0.67 per share Eligible shareholders must have bought the stock before 03 May 2021. Payment date: 05 May 2021. Trailing yield: 1.8%. Lower than top quartile of Italian dividend payers (4.0%). Lower than average of industry peers (2.1%). Reported Earnings • Mar 24
Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.7m (up 9.0% from FY 2019). Net income: €14.1m (up 67% from FY 2019). Profit margin: 24% (up from 16% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Dec 12
New 90-day high: €33.70 The company is up 49% from its price of €22.60 on 11 September 2020. The Italian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 1.0% over the same period. Valuation Update With 7 Day Price Move • Dec 07
Market bids up stock over the past week After last week's 17% share price gain to €33.30, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.7x. This compares to an average P/E of 21x in the Personal Products industry in Europe. Total returns to shareholders over the past three years are 183%. Is New 90 Day High Low • Nov 12
New 90-day high: €28.80 The company is up 24% from its price of €23.30 on 14 August 2020. The Italian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period. Reported Earnings • Nov 11
Third quarter 2020 earnings released: EPS €0.18 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €13.0m (down 9.4% from 3Q 2019). Net income: €1.74m (down 22% from 3Q 2019). Profit margin: 13% (down from 16% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year and the company’s share price has also increased by 30% per year. Is New 90 Day High Low • Oct 05
New 90-day high: €27.20 The company is up 13% from its price of €24.00 on 07 July 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 2.0% over the same period. Reported Earnings • Sep 18
First half earnings released Over the last 12 months the company has reported total profits of €14.2m, up 58% from the prior year. Total revenue was €57.9m over the last 12 months, up 16% from the prior year.